1st April 2023

ANGELMAN SYNDROME Alliance Announces 2024 Grant Call

The Angelman Syndrome Alliance (ASA) would like to announce our fourth biannual grant call, to fund research into Angelman syndrome.

Key dates

Applications open: 1st April 2023

Deadline for applications: 30th June 2023

Successful grant applicants notified: 1st January 2024

Grant funding period starts: 1st April 2024

The Angelman Syndrome Alliance (ASA) is a non-profit organization registered in the Netherlands, created by a partnership of organizations from around the world that are focused on supporting people with Angelman Syndrome, their loved ones, carers, and clinicians. By combining resources, knowledge, and a relentless dedication to initiate change, the ASA is uniquely positioned to drive advances in scientific knowledge about Angelman Syndrome. As a rare disease, funding for scientific research from major funders is limited. The ASA combines financial resources from small Angelman syndrome charities around the world to fund scientific research.

Angelman Syndrome is a genetic disorder that results from a loss of UBE3A gene activity which encodes the ubiquitin E3 ligase E6-AP. It is characterised by severe intellectual disability, lack of speech, motor coordination deficits, sleep disturbance, and usually a happy demeanour.

Researchers of any country are invited to apply for research grants covering ‘basic science’ research that can help support a better understanding of Angelman Syndrome and eventually lead to new treatments tackling the genetic & molecular processes underlying the condition.

Applicants can apply for up to €120,000. The duration of the grant is flexible, but the maximum duration is 4 years. A detailed written report to support the evaluation of the progress of the project will be required after completion of 50% of the anticipated grant duration and a final report at the end of the study. Researchers will also be required to present their results at the ASA biannual conferences.

ASA Members participating on Call 2023

AS parent organizations from Austria, Belgium, UK, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Portugal, Spain, Ukraine and the Nina Foundation

ASA Board

Manuel Trocado Costa Duarte, Portugal
Conny Schendler, Germany
Thomas Schramm, Austria
Katie Cunnea, UK
Emanuele Bedon, Italy

Scientific Advisory Board (SAB)

Prof. Hanoch Kaphzan, Israel – Chairman
Prof. Olga Peñagarikano, Spain
Prof. Luis Pereira de Almeida, Portugal
Prof. Jill Clayton-Smith, UK

How to apply

Registering for the grant can be done via the ASA website www.angelmanalliance.org

Applications must include:

- An abstract, including an introduction, objectives, methodology and scientific impact.
- An introduction to the research proposed, including how state of art research will be applied, work already achieved by the proposed investigator and their department in the area and discussion of the scientific and technological background of each element of the project.
- Hypothesis and research objectives.
- Detailed research program, including specific goals, methodology and work plan. Key scientific issues should be emphasized.
- Expected significance and impact of the project in all relevant aspects.
- Bibliography.
- A detailed budget & timeline of deliverables over the funding period.
- Curriculum vitae of the applicant(s).

All applications should be written in English language using Times New Roman, 10 point, 1.5 spaced.

Applicants will be responsible for ensuring all legal requirements in their countries can be met. For example, animal testing, human tissue samples, radiation, and these must be approved by the respective institutional review boards before funding can be released. All proposals, including cover letters, should be uploaded on the ASA website: https://angelmanalliance.org/index.php/research-grants

Questions about the grant application process should be directed to Dr. Katie Cunnea of the ASA Board: katie.cunnea@angelmanuk.org

Questions about research on Angelman Syndrome should be directed to Prof. Hanoch Kaphzan of the Scientific Advisory Board at: hkaphzan@univ.haifa.ac.il